Abstract:Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and drug resistance profiles of NA, we employed a high-throughput profiling system to quantify the replication capacity of NA mutants at the single-nucleotide level in mouse lung tissues. The fitness of NA mutants is generally correlated with natural mutation occurrence and is constrained by both the requirement to maintain protein stability and NA function. Leveraging this system, we profiled the drug resistance to the three most commonly used neuraminidase inhibitors (NAIs): zanamivir, oseltamivir, and peramivir. In addition to identifying previously reported drug resistance mutations, we validated novel mutants. Notably, we identified an allosteric mutation that confers resistance to all three drugs, which may affect drug binding by interfering with the tetramerization of NA. Moreover, the fitness cost associated with drug-resistant mutations may limit their widespread dissemination. In summary, we provided a parallel characterization of NA's fitness and drug resistance landscape in an context, which may guide the rational selection of antiviral drugs for optimal therapeutic efficacy and second-generation NAI development. IMPORTANCE NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA's mutational effect and drug resistance profiles is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs.

Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding

Binding Mechanism of Oseltamivir and Influenza Neuraminidase Suggests Perspectives for the Design of New Anti-Influenza Drugs

The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study.

Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors

Design, Synthesis and Biological Evaluation of "Multi-Site"-binding Influenza Virus Neuraminidase Inhibitors.

Structural and Functional Analysis of Laninamivir and Its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition.

Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity

Optimization of N-Substituted Oseltamivir Derivatives As Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.

Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.

Microsecond dynamics of H10N7 influenza neuraminidase reveals the plasticity of loop regions and drug resistance due to the R292K mutation

Functional And Structural Analysis Of Influenza Virus Neuraminidase N3 Offers Further Insight Into The Mechanisms Of Oseltamivir Resistance

Discovery of Novel "Dual-Site" Binding Oseltamivir Derivatives As Potent Influenza Virus Neuraminidase Inhibitors.

Novel Binding Patterns Between Ganoderic Acids and Neuraminidase: Insights from Docking, Molecular Dynamics and Mm/Pbsa Studies

Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.

Theoretical Studies on the Susceptibility of Oseltamivir Against Variants of 2009 A/H1N1 Influenza Neuraminidase.

A Novel N-heterocycles Substituted Oseltamivir Derivatives As Potent Inhibitors of Influenza Virus Neuraminidase: Discovery, Synthesis and Biological Evaluation

Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6

Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity

Rational Design of Tamiflu Derivatives Targeting at the Open Conformation of Neuraminidase Subtype 1

The hydrophobic side chain of oseltamivir influences type A subtype selectivity of Neuraminidase inhibitors.

Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo .